ContraFect Past Earnings Performance
Past criteria checks 0/6
ContraFect's earnings have been declining at an average annual rate of -15.1%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
-15.1%
Earnings growth rate
33.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How ContraFect makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -65 | 12 | 45 |
| 30 Sep 22 | 0 | -60 | 13 | 51 |
| 30 Jun 22 | 0 | -48 | 13 | 49 |
| 31 Mar 22 | 0 | -35 | 12 | 40 |
| 31 Dec 21 | 0 | -20 | 12 | 36 |
| 30 Sep 21 | 0 | -22 | 12 | 32 |
| 30 Jun 21 | 0 | -14 | 12 | 28 |
| 31 Mar 21 | 0 | -26 | 11 | 26 |
| 31 Dec 20 | 0 | -28 | 12 | 23 |
| 30 Sep 20 | 0 | -32 | 11 | 19 |
| 30 Jun 20 | 0 | -41 | 11 | 20 |
| 31 Mar 20 | 0 | -32 | 11 | 19 |
| 31 Dec 19 | 0 | -13 | 10 | 18 |
| 30 Sep 19 | 0 | 3 | 9 | 21 |
| 30 Jun 19 | 0 | 4 | 9 | 21 |
| 31 Mar 19 | 0 | -7 | 9 | 22 |
| 31 Dec 18 | 0 | -38 | 9 | 22 |
| 30 Sep 18 | 0 | -48 | 9 | 20 |
| 30 Jun 18 | 0 | -46 | 9 | 19 |
| 31 Mar 18 | 0 | -28 | 9 | 18 |
| 31 Dec 17 | 0 | -16 | 9 | 17 |
| 30 Sep 17 | 0 | -10 | 10 | 17 |
| 30 Jun 17 | 0 | -19 | 11 | 18 |
| 31 Mar 17 | 0 | -26 | 11 | 22 |
| 31 Dec 16 | 0 | -29 | 11 | 22 |
| 30 Sep 16 | 0 | -37 | 9 | 23 |
Quality Earnings: 22R is currently unprofitable.
Growing Profit Margin: 22R is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 22R is unprofitable, and losses have increased over the past 5 years at a rate of 15.1% per year.
Accelerating Growth: Unable to compare 22R's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 22R is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 22R's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.